Safety Information
Compounded drugs are permitted to be prescribed under federal law but are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing standards. A licensed medical provider may recommend certain doses of compounded semaglutide based on your individual evaluation.
Compounded semaglutide is an injectable prescription medication that may assist adults with obesity, or those who are overweight with weight-related medical issues, to lose weight and maintain that loss. It is intended to be used in combination with a reduced-calorie diet and increased physical activity.
It is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist intended for chronic weight management in adults with:
In animal studies, semaglutide has been linked to thyroid tumors, including medullary thyroid carcinoma (MTC). It is unknown whether compounded semaglutide poses the same risk in humans.
Tell your provider immediately if you notice:
If any of the following occur, stop treatment and seek immediate medical attention:
Report side effects to the FDA: www.fda.gov/medwatch or 1-800-FDA-1088.
Compounded semaglutide is prescription-only. For questions about your treatment or pharmacy, contact Craft Peptides:
Disclaimer: Ozempic®, Wegovy®, Saxenda®, and Victoza® are registered trademarks of Novo Nordisk. Zepbound® and Mounjaro® are trademarks of Eli Lilly. Craft Peptides is not affiliated with any of these companies or their products. The compounded medications provided through Craft Peptides' telehealth program are not made or endorsed by these companies.
Craft Peptides is a telehealth management platform providing administrative and operational support to independent, licensed healthcare providers. Craft Peptides does not provide medical or pharmacy services and does not influence clinical decisions.